Bausch Health Companies Inc
TSX:BHC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.2
14.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bausch Health Companies Inc
Bausch Health Companies Inc
Capital Expenditures
Bausch Health Companies Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Capital Expenditures
-$377m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Capital Expenditures
-CA$7.9m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Capital Expenditures
-$4.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Capital Expenditures
-CA$32.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Capital Expenditures
-$89.8m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bausch Health Companies Inc
Glance View
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 19,600 full-time employees. The firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.
See Also
What is Bausch Health Companies Inc's Capital Expenditures?
Capital Expenditures
-377m
USD
Based on the financial report for Sep 30, 2024, Bausch Health Companies Inc's Capital Expenditures amounts to -377m USD.
What is Bausch Health Companies Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
1%
Over the last year, the Capital Expenditures growth was -68%. The average annual Capital Expenditures growth rates for Bausch Health Companies Inc have been -10% over the past three years , -8% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
